Recommendable! An overview article.
"... More specifically, psychedelics transiently and indirectly alter glutamatergic signaling in ways that promote widespread neuroplasticity and emotional recalibration, while ketamine engages similar plasticity-related pathways through NMDA receptor inhibition, increasing glutamate release and AMPA receptor signaling. However, these drugs act broadly across the brain, producing intense, variable, and subjective effects.
This has motivated a shift toward precision neuroscience. Rather than globally altering brain activity, next-generation drugs are being designed to modulate dysfunctional circuitry in two complementary ways:
by targeting glutamatergic signaling in defined brain regions and circuits involved in fear, mood, and emotional regulation, and
by minimizing hallucinogenic or dissociative effects.
Psychedelics revealed the importance of circuit remodeling; precision approaches offer a safer, more scalable path to harness it. ..."
No comments:
Post a Comment